VIDEO: PSCA-targeted CAR T-cell therapy shows promise in prostate cancer subgroup

In this video, Tanya Dorff, MD, discusses findings from a phase 1 study assessing prostate stem cell antigen-targeted CAR T-cell therapy in patients with castration-resistant prostate cancer.
The findings were presented at the 2022 ASCO Genitourinary Cancers Symposium.
Dorff, section chief of the genitourinary disease program at City of Hope, noted that while the data presented were early phase results, “what I would want clinicians to take away is that CAR T-cell therapy — in our case targeting prostate stem cell antigen (PSCA) — is already showing the potential for

In this video, Tanya Dorff, MD, discusses findings from a phase 1 study assessing prostate stem cell antigen-targeted CAR T-cell therapy in patients with castration-resistant prostate cancer.
The findings were presented at the 2022 ASCO Genitourinary Cancers Symposium.
Dorff, section chief of the genitourinary disease program at City of Hope, noted that while the data presented were early phase results, “what I would want clinicians to take away is that CAR T-cell therapy — in our case targeting prostate stem cell antigen (PSCA) — is already showing the potential for